Seven-component antigen African swine fever nanoparticle vaccine

By combining multiple antigens of African swine fever virus with nanoparticles, a seven-component antigen African swine fever nanoparticle vaccine was prepared, which solved the problems of the existing vaccine in terms of immunity efficacy and safety, and achieved strong anti-African swine fever Effective protection of strains and suitable for large-scale production.

CN116672443BActive Publication Date: 2024-11-29LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202310647769.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-06-02
Publication Date
2024-11-29
Estimated Expiration
2043-06-02

AI Technical Summary

Technical Problem

The existing African swine fever vaccine, including subunit vaccines, poses biosafety risks such as insufficient immune efficacy and virulence residues. Although the gene deletion vaccine solves the problem of immune efficacy, it has safety risks, making it difficult to effectively protect the strong toxicity of African swine fever. attack of the plant.

Method used

A seven-component antigen African swine fever nanoparticle vaccine consisting of African swine fever virus P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein are used, wherein at least one antigen forms a binding to the nanoparticle carrier. , prepared by high-pressure homogenization or high-speed stirring and emulsification, to form nanoparticle vaccines to improve immune response and protective efficacy.

Benefits of technology

The seven-component antigen African swine fever nanoparticle vaccine not only produces a good immune response, but also provides ideal protective effect when the parent African swine fever strain is attacked, and has good safety. It is suitable for large-scale industrial production and has significant social and economic value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116672443B_ABST
    Figure CN116672443B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biotechnology, and specifically relates to a seven-component antigen African swine fever combination vaccine. The present invention first provides a seven-component antigen African swine fever nanoparticle combination composed of African swine fever virus antigens P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein, wherein at least one antigen forms a nanoparticle containing the antigen or its antigenic epitope with a nanoparticle carrier; the seven-component antigen African swine fever nanoparticle combination can stimulate the body to produce a strong immune response; secondly, the present invention prepares a vaccine comprising the above-mentioned seven-component antigen African swine fever nanoparticle combination, and the seven-component antigen African swine fever nanoparticle vaccine has a good immune protection rate against the parent African swine fever strong strain, has no biosafety risk, and breaks through the problem that the existing African swine fever subunit vaccines at home and abroad cannot provide effective immune protection for pigs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology, and specifically relates to a seven-component antigen African swine fever nanoparticle vaccine. Background Art

[0002] African swine fever (ASF) is the "number one killer" that threatens the world's pig farming industry and has been prevalent for more than a hundred years. In August 2018, African swine fever was introduced into my country, severely damaging my country's pig farming industry and causing unprecedented losses. So far, no commercial ASF vaccine has been available, which has become a pain point and problem for the pig farming industry, and is also a major national need. Scientific research at home and abroad has shown that ASF inactivated vaccines, subunit vaccines, and live vector vaccines still have not solved the problem of immune efficacy. Although gene-deficient vaccines have solved the problem of immune efficacy, there are residual virulence and biosafety risks. The African swine fever virus (ASFV) has a huge genome and encodes more than 150 viral proteins, most of which have unclear functions. Little is known about the antigens that induce and stimulate the immune system, which has become a key issue in creating an African swine fever vaccine with ideal immune efficacy.

[0003] Regarding subunit vaccines, Chinese patent CN115814071A discloses a subunit vaccine composed of African swine fever virus p34, p14, C129R, DP96R, A104R, p54, p17, p22, P72, and p30 proteins; Chinese patent CN115702928A discloses a subunit vaccine composed of African swine fever virus p34, p14, C129R, DP96R, A104R, p54, p22, P72 , p30 protein; Chinese patent CN112472801A discloses a subunit vaccine composed of African swine fever p30, p54, p72 and B602L; Chinese patent CN111658768A discloses a subunit vaccine comprising the surface envelope protein CD2V of African swine fever virus and at least one protein selected from the group consisting of the P72 protein of African swine fever virus, the P30 protein of African swine fever virus, and the P54 membrane structural protein of African swine fever virus. Although the above studies have disclosed subunit vaccines composed of different antigens, none of them systematically evaluated the immune efficacy of the vaccine. Further research by the applicant team also found that some of the antigen components involved in the above subunit vaccines have an ADE effect, which may seriously affect the protective efficacy of the subunit vaccine against strong strains of African swine fever. The ADE effect refers to the fact that after the virus-specific antibody binds to the virus, the antibody bound to the virus can bind to certain cells expressing FcR on the surface through the Fc segment, thereby causing the virus to enter these cells, thereby enhancing the infectivity of the virus.

[0004] Based on the above problems, the applicant first discovered a seven-component antigen African swine fever subunit vaccine composed of African swine fever virus P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein, and the subunit vaccine has an ideal protective efficacy against the virulent parent strain of African swine fever; on this basis, the applicant replaced at least one of the self-component antigens in the subunit vaccine with nanoparticles in the present invention to obtain a seven-component antigen African swine fever nanoparticle vaccine; the nanoparticle vaccine has better protective efficacy against the virulent parent strain of African swine fever. Summary of the invention

[0005] In response to the above technical problems, the present application has unexpectedly discovered a seven-component antigen African swine fever nanoparticle vaccine after a large number of experimental screening and evaluation studies. The nanoparticle vaccine can not only produce a better immune response and has good safety, but also provide ideal protective efficacy when challenged with the parent African swine fever virulent strain, specifically including the following contents:

[0006] In a first aspect, the present invention provides a seven-component antigen African swine fever nanoparticle combination, wherein the seven-component antigen African swine fever nanoparticle combination is composed of African swine fever virus antigens P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein, wherein at least one antigen and a nanoparticle carrier form a nanoparticle containing the antigen or an antigenic epitope thereof; the X protein is DP96R protein or a fusion protein of DP96R protein and P12 protein; the Y protein is P22 protein, or P17 protein, or a combination of P22 protein and P17 protein, or a fusion protein of P22 protein and P17 protein, or a fusion protein of P22 protein fragment and P17 protein fragment.

[0007] Preferably, the African swine fever virus is type II African swine fever virus.

[0008] Preferably, the type II African swine fever virus is ASFV CN / GS 2018.

[0009] Preferably, the amino acid sequence of the P34 protein is shown in SEQ ID NO.1; the amino acid sequence of the P30 protein is shown in SEQ ID NO.3; the amino acid sequence of the P54 protein is shown in SEQ ID NO.5 or SEQ ID NO.7; the amino acid sequence of the A104R protein is shown in SEQ ID NO.9; the amino acid sequence of the DP96R protein is shown in SEQ ID NO.11, and the amino acid sequence of the fusion protein of the DP96R protein and the P12 protein is shown in SEQ ID NO.13; the amino acid sequence of the C129R protein is shown in SEQ ID NO.15; the amino acid sequence of the P17 protein is shown in SEQ ID NO.17; the amino acid sequence of the P22 protein is shown in SEQ ID NO.19; the amino acid sequence of the fusion protein of the P17 protein fragment and the P22 protein fragment is shown in SEQ ID NO.21; the amino acid sequence of the fusion protein of the P17 protein and the P22 protein is shown in SEQ ID NO.23.

[0010] The seven-component antigen African swine fever nanoparticle combination consists of African swine fever virus P34 protein, P30 protein, A104R protein, X protein, C129R protein, Y protein and nanoparticles expressing P54 protein.

[0011] Preferably, the seven-component antigen African swine fever nanoparticle combination consists of nanoparticles expressing African swine fever virus antigens P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein, respectively.

[0012] Preferably, the nanoparticle carrier includes a natural or synthetic polymer nanoparticle carrier, a lipid nanoparticle carrier, a protein nanoparticle carrier, or an inorganic material nanoparticle carrier.

[0013] Preferably, the natural or synthetic polymer nanoparticle carrier is selected from polyethylene glycol, polyester, polylactic acid, block polymer, polyethyleneimine, chitosan.

[0014] Preferably, the preparation method of the seven-component antigen African swine fever nanoparticle combination is: dispersing a natural or synthetic polymer nanoparticle carrier in a polymerization medium to form uniform and stable polymer nanoparticles; mixing purified P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein with the polymer nanoparticles respectively, and preparing the seven-component antigen African swine fever nanoparticle combination by high-pressure homogenization or high-speed stirring emulsification.

[0015] Preferably, the lipid nanoparticle carrier is selected from ionic lipids, phospholipids, cholesterol, and PEG-lipid nanomaterials.

[0016] Preferably, the preparation method of the seven-component antigen African swine fever nanoparticle combination is: respectively mixing purified P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein with lipid nanoparticles dissolved in an organic phase in a volume ratio of 1:1, and preparing the seven-component antigen African swine fever nanoparticle combination by a microfluidic device.

[0017] Preferably, the inorganic material nanoparticle carrier is selected from metal nanomaterials, inorganic oxide nanomaterials, and inorganic semiconductor nanomaterials.

[0018] Preferably, the inorganic material nanoparticle carrier is selected from gold nanomaterials.

[0019] Preferably, the preparation method of the seven-component antigen African swine fever nanoparticle combination is: respectively preparing purified P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein into antigen solutions, taking a uniformly dispersed gold nanoparticle solution and the above antigen solutions and mixing them evenly to prepare the seven-component antigen African swine fever nanoparticle combination.

[0020] Preferably, the protein nanoparticle carrier is selected from ferritin, flagellin, silk protein, small heat shock protein, and virus-like particle assembly protein.

[0021] Preferably, the protein nanoparticle carrier is ferritin.

[0022] Preferably, the preparation method of the seven-component antigen African swine fever nanoparticle combination is: adding linkers to the carboxyl termini of P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein respectively, and then mixing them with a self-assembled ferritin nanoparticle carrier, or fusing gene fragments encoding P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein with ferritin nanoparticle carrier genes for expression, and purifying to obtain the seven-component antigen African swine fever nanoparticle combination.

[0023] Preferably, the amino acid sequence of the linker is as shown in SEQ ID NO.25, and the nucleotide sequence is as shown in SEQ ID NO.26.

[0024] Preferably, the amino acid sequence of the ferritin is as shown in SEQ ID NO.27, and the nucleotide sequence is as shown in SEQ ID NO.28.

[0025] Preferably, the composition ratio of the P34 protein, the P30 protein, the P54 protein, the A104R protein, the X protein, the C129R protein and the Y protein is 1-6: 1-6: 1-6: 1-6: 1-6: 1-6: 1-6.

[0026] Preferably, the composition ratio of the P34 protein, the P30 protein, the P54 protein, the A104R protein, the X protein, the C129R protein and the Y protein is 1-2:1:1-2:1:1-2:1:1.

[0027] Preferably, the composition ratio of the P34 protein, the P30 protein, the P54 protein, the A104R protein, the X protein, the C129R protein and the Y protein is 2:1:1-2:1:2:1:1.

[0028] Preferably, the composition ratio of the P34 protein, the P30 protein, the P54 protein, the A104R protein, the X protein, the C129R protein and the Y protein is 2:1:1:1:2:1:1.

[0029] Preferably, the concentrations of the P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein are all greater than or equal to 50 μg / ml.

[0030] Preferably, the concentrations of the P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein are all greater than or equal to 90 μg / ml.

[0031] Preferably, the concentration of the protein is greater than or equal to 150 μg / ml.

[0032] Preferably, the concentration of the protein is 150-2400 μg / ml.

[0033] Preferably, the concentrations of the P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein are 400 μg / ml, 200 μg / ml, 200 μg / ml, 400 μg / ml, 200 μg / ml and 200 μg / ml respectively.

[0034] Preferably, the concentrations of the P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein are 400 μg / ml, 200 μg / ml, 400 μg / ml, 200 μg / ml, 400 μg / ml, 200 μg / ml and 200 μg / ml respectively.

[0035] In a second aspect, the present invention provides the use of the seven-component antigen African swine fever nanoparticle combination described in the first aspect above in the preparation of a drug for preventing or treating African swine fever virus infection.

[0036] In a third aspect, the present invention provides the use of the seven-component antigen African swine fever nanoparticle combination described in the first aspect above in the preparation of biological products for preventing African swine fever virus infection.

[0037] In a fourth aspect, the present invention provides a seven-component antigen African swine fever nanoparticle vaccine, which is composed of the seven-component antigen African swine fever nanoparticle combination described in the first aspect and a pharmaceutically acceptable adjuvant.

[0038] Preferably, the adjuvant includes: one or more of chemical immune adjuvants, microbial immune adjuvants, plant immune adjuvants, and biochemical immune adjuvants.

[0039] The beneficial effects of the present invention are as follows: (1) The present invention provides a seven-component antigen African swine fever nanoparticle combination consisting of African swine fever virus antigens P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein, wherein at least one antigen is a nanoparticle expressing an antigen, the X protein is DP96R protein or a fusion protein of DP96R protein and P12 protein; the Y protein is P22 protein, or P17 protein, or a combination of P22 protein and P17 protein, or a fusion protein of P22 protein and P17 protein, The seven-component antigen African swine fever nanoparticle combination can produce a good immune response; (2) the seven-component antigen African swine fever nanoparticle vaccine prepared by adding a vaccine adjuvant to the seven-component antigen African swine fever nanoparticle combination of the present invention can provide better protection efficiency when attacked by the parent African swine fever virulent strain; (3) the seven-component antigen African swine fever nanoparticle vaccine described in this application has good safety; (4) the seven-component antigen African swine fever nanoparticle vaccine described in this application has a simple preparation process, is suitable for large-scale industrial production, and has great social and economic value. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1 The purification process of nanoparticle carrier protein SC-Fer, where M: protein molecular weight marker; 1: sample before purification; 2: sample after purification;

[0041] Figure 2The purification process of African swine fever virus nanoantigen protein, where M: protein molecular weight marker; 1: purified nanoparticle carrier protein SC-Fer; 2: purified African swine fever P54 antigen protein; 3: mixed sample of SC-Fer and P54 antigen protein; 4: purified African swine fever virus P54 nanoantigen protein.

[0042] Figure 3 Transmission electron microscopy identification results of African swine fever virus P54 nanoantigen protein. DETAILED DESCRIPTION

[0043] In order to make the technical means, creative features, objectives and effects of the present invention easy to understand, the present invention is further described below in conjunction with specific implementation methods. However, the protection scope of the present invention is not limited to the following embodiments.

[0044] The experiments described in the following examples were performed with biosafety permits and African swine fever laboratory activity permits:

[0045] In accordance with the relevant requirements of biosafety level 3 laboratories (BSL-3) and African swine fever-related biosafety, the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences has obtained the Ministry of Agriculture's permission to conduct research on highly pathogenic ASFV pathogens and animals through the Biosafety Committee of the Lanzhou Veterinary Research Institute, the Laboratory Animal Ethics Committee, the Biosafety Committee of the Chinese Academy of Agricultural Sciences, the Laboratory Animal Ethics Committee of the Lanzhou Veterinary Research Institute, and the Biosafety Committee of the Lanzhou Veterinary Research Institute. The research has been filed with the Ministry of Agriculture and Rural Affairs and meets the national biosafety level requirements.

[0046] The experimental cells, viruses and plasmids described in the following examples are from:

[0047] BL21(DE3) competent cells and pET28a expression vector were purchased from Shanghai Solebow Biotechnology Co., Ltd. The suspension cultured CHO cells were preserved by Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences.

[0048] The ASFV protein expression plasmids were cloned by classical molecular gene cloning method, using ASFV cDNA as template, PCR amplified different viral protein coding regions and connected to pCMV-C-Flag vector. Primary porcine alveolar macrophages (PAM) were prepared by our laboratory (separated and prepared from porcine lung washing).

[0049] LB liquid medium (dry powder) and LB solid medium (dry powder) were purchased from Beijing Solebow Technology Co., Ltd.; kanamycin, IPTG, and X-Gal were purchased from Shanghai Solebow Technology Co., Ltd.; Gel Extraction Kit (100) and PlasmidMini Kit I (100) were purchased from OMEGA, USA; conventional molecular and chemical reagents were purchased from Sinopharm Chemical Reagent Co., Ltd. PureLinK HiPure Plasmid Maxiprep Plasmid Extraction Kit, ExpiSf TM Protein ProductionKit, ExpiFectamine TM CHO Transfection Kit was purchased from Invitrogen; DNA Marker was purchased from TaKaRa.

[0050] Type II African swine fever virus strain ASFV CN / GS 2018 was from the National African Swine Fever Regional Laboratory (Lanzhou), belonging to genotype II, with a virus titer of 1×10 5 HAD 50 / mL, which is the 4th generation seed virus after PAM cell expansion. It was deposited in the China Center for Type Culture Collection on December 21, 2020, with the deposit number CCTCC NO: V202096; deposit address: Wuhan University, Wuhan, China; Tel: 027-68752319.

[0051] According to the viral protein gene sequence encoded by the ASFV CN / GS / 2018 isolate, we designed and synthesized different viral protein coding region fragments to construct eukaryotic expression vectors. We designed each gene expression sequence through codon optimization (including eliminating rare codons, adjusting GC content, etc.), sent the optimized gene sequence to the company for synthesis, and constructed prokaryotic expression vectors.

[0052] Experimental rabbits: Healthy New Zealand male rabbits weighing about 2.0 kg were purchased from the Experimental Animal Center of Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences.

[0053] Pigs: healthy pigs, all purchased from farms without ASFV prevalence, PCV2 antigen test was negative, and ASFV, PRRSV antigen and antibody tests were all negative.

[0054] definition:

[0055] The term "molecular chaperone" refers to a class of proteins that are not related in sequence but have common functions. They help other polypeptide-containing structures to complete the correct assembly within the cell, and are separated from them after assembly. They do not constitute components of these protein structures when they perform their functions.

[0056] The term "truncated protein" refers to a protein without the transmembrane region or the extracellular region of the protein.

[0057] The term "antigen" refers to a substance that can induce an immune response in the body, that is, a substance that can be specifically recognized and bound by the antigen receptors (TCR / BCR) on the surface of T / B lymphocytes, activate T / B cells, cause them to proliferate and differentiate, produce immune response products (sensitized lymphocytes or antibodies), and can specifically bind to corresponding products in vivo and in vitro.

[0058] The terms "vaccine", "vaccine composition" and "subunit vaccine" refer to a pharmaceutical composition containing African swine fever virus protein antigens that can induce, stimulate or enhance the immune response of pigs against African swine fever, a biological preparation that can provide a protective response in animals, wherein the vaccine has been delivered and cannot cause severe disease.

[0059] Furthermore, the “vaccine”, “vaccine composition” and “subunit vaccine” comprise one or more adjuvants, excipients, carriers and diluents.

[0060] Furthermore, the adjuvant includes one or more of chemical immune adjuvants, microbial immune adjuvants, plant immune adjuvants, and biochemical immune adjuvants.

[0061] Further, the chemical immune adjuvants include aluminum hydroxide, Freund's adjuvant, mineral oil, Span, etc.; the microbial immune adjuvants include mycobacteria, lipopolysaccharide, muramyl dipeptide, murine peptide, fat-soluble wax D, short bacillus; the plant immune adjuvants include polysaccharides extracted from plants or large fungi, such as tuckahoe polysaccharide, safflower polysaccharide, Chinese herbal medicine, etc.; the biochemical immune adjuvants include thymosin, transfer factor, interleukin, etc. Preferred adjuvants can be nano-adjuvants, biological adjuvants, interleukins, interferons, etc.

[0062] Furthermore, the "vaccine", "vaccine composition" and "subunit vaccine" can also be used to prepare combined vaccines, such as combined with other vaccines for pigs;

[0063] Further, the administration of the "vaccine", "vaccine composition", "subunit vaccine" can be conveniently administered, such as intramuscular injection, intranasal, oral, subcutaneous, transdermal and vaginal routes. The "vaccine", "vaccine composition", "subunit vaccine" can be administered after a prime-boost regimen; for example, after the first vaccination, the subject can receive a second booster administration after a period of time (e.g., about 7, 14, 21 or 28 days). Typically, the dose of the booster administration is the same as or lower than the dose used for the primary immunization. In addition, a third booster immunization may also be performed, such as 2-3 months, 6 months or one year after immunization.

[0064] The term "prevention" when referring to African swine fever virus infection means inhibiting the replication of African swine fever virus, inhibiting the spread of African swine fever virus or preventing African swine fever virus from taking root in its host, and alleviating the symptoms of diseases or conditions caused by African swine fever virus infection.

[0065] Example 1 Preparation of seven-component antigen nanoparticles

[0066] The expression and identification of African swine fever virus P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein, and Y protein were carried out with reference to the content of patent document CN202310374606.0.

[0067] Preparation of P54 protein nanoparticles: First, a linker is added to the carboxyl terminus of the P54 protein (the amino acid sequence of the P54 protein is shown in SEQ ID NO.7, and the coding gene sequence is shown in SEQ ID NO.8 (in order to facilitate purification and expression, this application uses a truncated protein of the P54 protein (removing the transmembrane region), the amino acid sequence is shown in SEQ ID NO.5, and the coding gene sequence is shown in SEQ ID NO.6), the amino acid sequence of the linker is shown in SEQ ID NO.25, and the nucleotide sequence is shown in SEQID NO.26; then, the P54 protein after the linker is added is expressed and purified according to the method described in the patent document CN202310374606.0.

[0068] Next, the nanoparticle carrier protein SC-Fer was prepared by an E. coli expression system, the amino acid sequence of which is shown in SEQ ID NO.27, and the nucleotide sequence of which is shown in SEQ ID NO.28.

[0069] The vector pET28-SC-Fer was synthesized by Beijing BGI Genomics Co., Ltd. The vector was transformed into E.coli DH5α, spread on LB solid medium containing kanamycin (Kanamycin 50 mg / L), cultured at 37°C, and positive clones were selected. After sequencing verification, the SC-Fer protein was induced to express. The correctly sequenced recombinant plasmid was transformed into E.coli BL21 (DE3) competent cells. A single colony containing the recombinant plasmid was picked on the LB solid medium containing 50 mg / L kanamycin to obtain a positive clone. The above positive clone was inoculated into LB liquid medium containing 50 mg / L kanamycin and cultured at 37°C overnight. The obtained bacterial solution was inoculated into 100 mL LB liquid medium containing 50 mg / L kanamycin at a volume ratio of 1:100, and cultured at 37°C and 220r / min with shaking until the mid-logarithmic phase (OD 600The expression was induced when the pH value reached 0.6-0.8, the final concentration of the inducer IPTG was 0.5mmol / L, and the optimal induction expression conditions were 16℃, 220r / min and 14h. After the induction was completed the next day, the bacterial solution was centrifuged to collect the precipitate, and the bacteria were resuspended in 10mL of Binding Buffer (pH8.0). Lysozyme (1g / L) was added and ice-bathed for 30min, and then the bacteria were broken by low-temperature ultrasonic wave (ultrasonic time 5s, interval 5s, working time 10min). The supernatant of the ultrasonic broken bacteria was filtered through a 0.45μm filter and purified by molecular sieve. The SC-Fer protein sample purified by molecular sieve was collected. The purification process is shown in Figure 1 .

[0070] The SC-Fer protein purified by molecular sieve and the P54 protein after adding the linker were mixed at a mass ratio of 1:1, and then kept at 4°C for 4 hours before molecular sieve purification. The antigen protein nanoparticles purified by molecular sieve were collected. The purification process is shown in Figure 2 The results of transmission electron microscopy identification of nanoparticle antigens are shown in Figure 3 .

[0071] In this example, the African swine fever virus P54 protein is taken as an example, and ferritin is selected as a nanoparticle carrier to prepare P54 protein nanoparticles. The preparation method of other antigen protein nanoparticles described in this application is the same as the preparation method of P54 protein nanoparticles, and the main difference lies in the different sequences of the corresponding antigen proteins.

[0072] This application only takes the ferritin nanoparticle carrier SC-Fer as an example to construct nanoparticles expressing antigenic proteins, but the nanoparticles described in this application are not limited to SC-Fer. Those skilled in the art can also select other forms of nanoparticle carriers to prepare nanoparticles containing the antigen or its antigenic epitope described in this application. On the basis that the ferritin nanoparticles described in this application have good immune protection efficacy, other forms of nanoparticles described in this application also have the same protection efficacy.

[0073] Example 2 Immune protection test of seven-component antigen African swine fever nanoparticle vaccine

[0074] 1. Configuration of the seven-component antigen African swine fever nanoparticle vaccine

[0075] After a large number of preliminary research experiments, the present application found that the seven-component African swine fever virus antigen protein combination described in the present application has good protective efficacy against the parent African swine fever virulent strain, wherein any one of the antigens in the antigen protein combination is replaced with nanoparticles, which has better immune protection efficacy. On this basis, the present application uses the following two combinations to prepare two seven-component antigen African swine fever nanoparticle vaccines as an example to evaluate the immune protection efficacy, as follows:

[0076] First, refer to the following content to obtain component antigen African swine fever nanoparticle combinations with different ratios, and then fully mix and emulsify the component antigen African swine fever nanoparticle combinations with an equal amount of ISA 201 adjuvant (Seppic, France) to prepare the seven-component antigen African swine fever nanoparticle vaccine 1-2.

[0077] Vaccine 1: P34 protein 400μg / ml, P30 protein 200μg / ml, P54 protein nanoparticles 400μg / ml, A104R protein 200μg / ml, X protein 400μg / ml, C129R protein 200μg / ml, Y protein 200μg / ml; adjuvant 50%;

[0078] Vaccine 2: P34 protein nanoparticles 400 μg / ml, P30 protein nanoparticles 200 μg / ml, P54 protein nanoparticles 400 μg / ml, A104R protein nanoparticles 200 μg / ml, X protein nanoparticles 400 μg / ml, C129R protein nanoparticles 200 μg / ml, Y protein nanoparticles 200 μg / ml; adjuvant 50%.

[0079] 2. Immunoassay

[0080] Detection kits: African swine fever virus fluorescence PCR detection kit, African swine fever virus blocking ELISA antibody detection kit, porcine circovirus type II direct amplification fluorescence quantitative PCR antigen detection kit, provided by Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences; RealPCR PRRSV-2RNA detection premix, porcine reproductive and respiratory syndrome virus antibody X3 detection kit, purchased from IDEXX.

[0081] The test virus ASFV CN / GS / 2018 strain, numbered: ASFV CN / GS / 2018 / 1901, ASFV CN / GS / 2018 / 2001, was provided by the Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences.

[0082] Experimental animals: 60-75 days old experimental pigs were all purchased from pig farms where ASFV, PRRSV and PCV-2 were not prevalent. The ASFV and PRRSV antigen and antibody tests were negative, and the PCV-2 antigen test was negative.

[0083] 2.1 Animal immunization

[0084] The seven-component antigen African swine fever nanoparticle vaccines 1-2 prepared above were used to immunize 60-75 day old test pigs, 5 pigs were immunized with each vaccine, by intramuscular injection behind the ear, 2 ml / head, and 21 days after the first immunization, the other side was injected intramuscularly behind the ear, 2 ml / head, for booster immunization. At the same time, 5 pigs were immunized with PBS as a control.

[0085] 2.2 Evaluation of virus attack

[0086] 14 days after booster vaccination, ASFV CN / GS / 2018 strain was used for challenge evaluation, with a challenge dose of 1.25HAD 50 / 3ml / head (equivalent to 5MLD). Observe continuously for 21 days after the infection, measure the rectal temperature daily, and record the clinical symptoms. All the control pigs became ill, and 5 / 5 died during the test period. The infection model was successfully constructed; the rectal temperature of the immunized pigs should not exceed 40.5℃; if the rectal temperature is ≥40.5℃, the retention should not exceed 2 days; no typical clinical symptoms caused by African swine fever virus infection (such as depression, loss of appetite or loss of appetite, vomiting, cyanosis of the ears or the whole body, bleeding from natural orifices) appeared; no death caused by African swine fever virus infection occurred during the test period. If the above 3 items are met, it is judged as protection. The vaccine protection rate is calculated based on the number of protected immunized pigs.

[0087] 2.3 Sample collection

[0088] On the 5th, 10th, 15th and 21st days after infection, 5 ml of blood was collected from each pig (4 ml for serum separation and 1 ml for preparation of anticoagulant blood (EDTA-K2)), and anal swab samples were also collected and stored at -70°C or below.

[0089] 3. Results

[0090] 3.1 Immune efficacy of seven-component antigen African swine fever nanoparticle vaccine

[0091] The results of the immune protection efficacy of the seven-component antigen African swine fever nanoparticle vaccine are shown in Table 1, indicating that the nine-seven-component antigen African swine fever nanoparticle vaccine described in the present application has good protection efficiency against the parental strong strain.

[0092] Table 1 The protection ratio of different vaccines against virus

[0093] Vaccine No. Attack and protection ratio Vaccine 1 5 / 5 Vaccine 2 5 / 5 Comparison 0 / 5

[0094] 3.2 Body temperature monitoring and clinical symptom observation of experimental pigs after virus challenge

[0095] The immune-protected test pigs had normal body temperature or body temperature ≥40.5℃ for no more than 2 days during the test period, grew healthily, and did not show typical clinical symptoms caused by African swine fever virus infection (depression, loss of appetite or loss of appetite, vomiting, cyanosis of the ears or skin, bleeding from natural orifices); the unprotected pigs began to have fever from the third day after the challenge, with body temperature reaching above 41℃, and showed typical clinical symptoms of African swine fever, and all died from the 7th to the 16th day after the challenge. The pigs in the control group began to have fever from the third day after the challenge, with body temperature reaching above 41℃, and all died from the 8th to the 15th day after the challenge.

[0096] 3.2 Results of nucleic acid testing of experimental pigs after virus challenge

[0097] No ASFV CN / GS / 2018 was detected in the immune-protected test pigs during the test period.

[0098] It should be noted that each component in the component antigen African swine fever nanoparticle vaccine described in this application has an ideal protection efficiency when the concentration is greater than or equal to 50 μg / ml.

[0099] The above results show that: (1) the present invention provides a seven-component antigen African swine fever nanoparticle combination consisting of African swine fever virus antigens P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein, wherein at least one antigen is a nanoparticle expressing an antigen, the X protein is DP96R protein or a fusion protein of DP96R protein and P12 protein; the Y protein is P22 protein, or P17 protein, or a combination of P22 protein and P17 protein, or a fusion protein of P22 protein and P17 protein, and the The seven-component antigen African swine fever nanoparticle combination described in the present invention can produce a good immune response; (2) the seven-component antigen African swine fever nanoparticle vaccine prepared by adding a vaccine adjuvant to the seven-component antigen African swine fever nanoparticle combination described in the present invention can provide better protection efficiency when attacked by the parent African swine fever virulent strain; (3) the seven-component antigen African swine fever nanoparticle vaccine described in this application has good safety; (4) the seven-component antigen African swine fever nanoparticle vaccine described in this application has a simple preparation process, is suitable for large-scale industrial production, and has great social and economic value.

Claims

1. A seven-component antigen African swine fever nanoparticle combination, characterized in that: The seven-component antigen African swine fever nanoparticle combination consists of African swine fever virus antigens P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein, wherein at least one antigen protein forms a nanoparticle containing the antigen with a nanoparticle carrier; the X protein is a fusion protein of DP96R protein and P12 protein; the Y protein is a fusion protein of P22 protein fragment and P17 protein fragment; the composition ratio of the P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein is 1-6:1-6:1-6:1-6:1-6:1-6; the concentrations of the P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein are all 150-2400 μg / ml; the amino acid sequence of the P34 protein is as shown in SEQ ID NO.1; the amino acid sequence of the P30 protein is shown in SEQ ID NO.3; the amino acid sequence of the P54 protein is shown in SEQ ID NO.5 or SEQ ID NO.7; the amino acid sequence of the A104R protein is shown in SEQ ID NO.9; the amino acid sequence of the fusion protein of the DP96R protein and the P12 protein is shown in SEQ ID NO.13; the amino acid sequence of the C129R protein is shown in SEQ ID NO.15; the amino acid sequence of the fusion protein of the P17 protein fragment and the P22 protein fragment is shown in SEQ ID NO.

21.

2. The seven-component antigen African swine fever nanoparticle combination as claimed in claim 1, characterized in that: The African swine fever virus is type II African swine fever virus.

3. The seven-component antigen African swine fever nanoparticle combination as claimed in claim 2, characterized in that: The type II African swine fever virus is ASFV CN / GS2018.

4. The seven-component antigen African swine fever nanoparticle combination as claimed in claim 1, characterized in that: The seven-component antigen African swine fever nanoparticle combination consists of African swine fever virus P34 protein, P30 protein, A104R protein, X protein, C129R protein, Y protein and nanoparticles expressing P54 protein.

5. The seven-component antigen African swine fever nanoparticle combination as claimed in claim 1, characterized in that: The seven-component antigen African swine fever nanoparticle combination consists of nanoparticles that respectively express African swine fever virus antigens P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein.

6. The seven-component antigen African swine fever nanoparticle combination as claimed in claim 1, characterized in that: The nanoparticle carriers include natural or synthetic polymer nanoparticle carriers, lipid nanoparticle carriers, protein nanoparticle carriers, and inorganic material nanoparticle carriers.

7. The seven-component antigen African swine fever nanoparticle combination as claimed in claim 6, characterized in that: The nanoparticle carrier is a natural or synthetic polymer nanoparticle carrier, and the natural or synthetic polymer nanoparticle carrier is selected from polyethylene glycol, polyester, polylactic acid, block polymer, polyethyleneimine, and chitosan; the preparation method of the seven-component antigen African swine fever nanoparticle combination is: dispersing the natural or synthetic polymer nanoparticle carrier in a polymerization medium to form uniform and stable polymer nanoparticles; and mixing purified P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein, and Y protein with the polymer nanoparticles respectively, and preparing the seven-component antigen African swine fever nanoparticle combination by high-pressure homogenization or high-speed stirring emulsification.

8. The seven-component antigen African swine fever nanoparticle combination as claimed in claim 6, characterized in that: The nanoparticle carrier is a lipid nanoparticle carrier, and the lipid nanoparticle carrier is selected from ionic lipids, phospholipids, cholesterol, and PEG-lipid nanomaterials; the preparation method of the seven-component antigen African swine fever nanoparticle combination is: purified P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein are mixed with lipid nanoparticles dissolved in an organic phase in a volume ratio of 1:1, and the seven-component antigen African swine fever nanoparticle combination is prepared by a microfluidic device.

9. The seven-component antigen African swine fever nanoparticle combination as claimed in claim 6, characterized in that: The inorganic material nanoparticle carrier is selected from metal nanomaterials, inorganic oxide nanomaterials, and inorganic semiconductor nanomaterials; the preparation method of the seven-component antigen African swine fever nanoparticle combination is: purified P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein are respectively prepared into antigen solutions, and a uniformly dispersed inorganic material nanoparticle solution and the above antigen solution are respectively mixed uniformly to prepare the seven-component antigen African swine fever nanoparticle combination.

10. The seven-component antigen African swine fever nanoparticle combination according to claim 6, characterized in that: The protein nanoparticle carrier is selected from ferritin, flagellin, fibroin, small heat shock protein, and virus-like particle assembly protein; the preparation method of the seven-component antigen African swine fever nanoparticle combination is: adding linkers to the carboxyl termini of P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein respectively, and then mixing them with the self-assembled protein nanoparticle carrier, or fusing gene fragments encoding P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein with protein nanoparticle carrier genes, and purifying to obtain the seven-component antigen African swine fever nanoparticle combination.

11. The seven-component antigen African swine fever nanoparticle combination as claimed in claim 1, characterized in that: The concentrations of the P34 protein, P30 protein, P54 protein, A104R protein, X protein, C129R protein and Y protein are 400 μg / ml, 200 μg / ml, 400 μg / ml, 200 μg / ml, 400 μg / ml, 200 μg / ml and 200 μg / ml respectively.

12. Use of the seven-component antigen African swine fever nanoparticle combination as described in any one of claims 1 to 11 in the preparation of a drug for preventing or treating African swine fever virus infection, or a biological product for preventing African swine fever virus infection.

13. A seven-component antigen African swine fever nanoparticle vaccine, characterized in that: The seven-component antigen African swine fever nanoparticle vaccine is composed of the seven-component antigen African swine fever nanoparticle combination described in any one of claims 1-11 and a pharmaceutically acceptable adjuvant.

14. The seven-component antigen African swine fever nanoparticle vaccine according to claim 13, characterized in that: The adjuvant includes: one or more of chemical immune adjuvants, microbial immune adjuvants, plant immune adjuvants, and biochemical immune adjuvants.

Citation Information

Patent Citations

  • Multi-component subunit vaccine for African swine fever, and preparation method and application of multi-component subunit vaccine

    CN111658768A

  • DNA vaccine and subunit vaccine of African swine fever p30, p54, p72 and B602L, and preparation method and application thereof

    CN112472801A

  • African swine fever virus subunit vaccine composition as well as preparation method and application thereof

    CN115814071A

  • Nine-component antigen African swine fever subunit vaccine

    CN116589539A

  • African swine fever virus vaccine and preparation method thereof

    CN112876570A